Bristol Halts HCV Trial Of Inhibitex Nuc Due To Possible Cardiac Toxicity

Bristol had paid $2.5 billion to buy Inhibitex and its Phase II nucleoside polymerase inhibitor in hopes of keeping pace with Gilead in the race to develop the first all-oral combination of direct-acting antivirals for hepatitis C.